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Abstract. Background/Aim: Preclinical studies on metformin
use and endometrial cancer have been promising but
epidemiological studies have reported variable results. This
study aimed to assess if metformin use is associated with
endometrial cancer aggressiveness and survival in women
with type 2 diabetes (T2D). Patients and Methods: This
retrospective hospital-based cohort consisted of women with
T2D who were treated for endometrial cancer at the Oulu
University Hospital, Finland, between 2007 and 2014.
Results: The sample size was 121 patients: 58 metformin users
and 63 metformin non-users. Intriguingly, type 2 histology,
deep myometrial invasion and the presence of lymphovascular
invasion were more common in the metformin user group.
However, metformin use showed no association with overall
survival and progression-free survival. Conclusion: Metformin
use was associated with poorer prognostic factors in
endometrial cancer patients with T2D. 
Endometrial cancer is the fifth most common cancer type in
women worldwide (1). The age-standardised incidence of
endometrial cancer is rising mostly due to lifestyle factors
such as obesity (2). Type 2 diabetes (T2D) is the most
rapidly increasing chronic disease globally, and has been
estimated that more than 460 million adults have diabetes,
with more than 90% of them suffering from T2D (3).
Although, T2D and endometrial cancer share some risk
factors, diabetes itself seems to be an independent risk factor
for endometrial cancer (4). 
The majority of endometrial cancers are diagnosed at an early
stage (5). Regarding early endometrial cancer, the five-year
survival rate is 95% but decreases to as low as 16% in stage IV
cancer (6). Endometrial cancers are traditionally classified as
type 1 and type 2 cancers and type 1 endometrial cancers are
more frequent and have a better prognosis than type 2 cancers
(7). Type 2 endometrial cancers are poorly differentiated and
are more commonly identified by their deep invasion into the
myometrium, higher frequency in pelvic lymph node metastases
and decreased sensitivity to progesterone (7).
Metformin is the main first-line therapy for T2D (8). In the
treatment of hyperglycaemia, metformin reduces the hepatic
glucose outlay, increases peripheral tissue sensitivity and
stimulates glucagon-like peptide-1 secretion (9). Metformin
is also weight neutral (9) and has favourable effects on cancer
cells both directly and indirectly (10). It sensitises tissues to
insulin, decreases hepatic gluconeogenesis and reduces
circulating insulin levels, and these effects indirectly lead to
both reduced tyrosine kinase activation and phospha-
tidylinositol-3-kinase signalling (10). 
Metformin has shown multiple molecular mechanisms in
endometrial cancer cells (11). In in vitro studies, metformin
seems to inhibit the proliferation and invasion of both
endometrioid and non-endometrioid endometrial cancer cells
(12-14). Metformin activates AMP-activated protein kinase
and this leads to inhibition of mammalian target of rapamycin
(15). In addition, it induces apoptosis (15), inhibits oxidative
phosphorylation at the mitochondrial level and inhibits
epithelial-to-mesenchymal transition (11). Metformin has
been shown to synergize with chemotherapy and progesterone
treatment in endometrial cancer cells (11). In addition, a
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meta-analysis of previous epidemiological studies indicated
that metformin users have a better overall survival (OS) rate
and a decreased risk of endometrial cancer recurrence (16).
This retrospective study was aimed to explore whether
metformin users diagnosed with endometrial cancer have a
less aggressive cancer phenotype or better survival rate in a
hospital-based cohort with comprehensive clinical data.
Patients and Methods
Patients. The data of the patients included in this study were
obtained from Oulu University Hospital records. These records
included information on the patients’ age at the time of diagnosis,
parity, antidiabetic medication (ADM) and body mass index (BMI).
In addition, we obtained information on endometrial cancer such as
stage, histology, myometrial invasion, lymphovascular invasion
(LVI), oestrogen receptor (ER) status, residual tumour after the
surgery, progression and death from hospital records. All
endometrial cancer diagnoses were based on histology. Stages were
rechecked and fitted to the current International Federation of
Gynaecology and Obstetrics (FIGO) stage (17). Endometrial cancers
were categorised as type 1 and type 2 cancers according to their
histology, so that grade 1 and grade 2 endometrioid endometrial
cancers (n=63 and n=27, respectively) and mucinous (n=1) cancers
were labelled as type 1 cancers, whereas grade 3 endometrioid
(n=11), serous (n=13), clear cell (n=1), mixed high grade (n=3),
undifferentiated endometrial cancers (n=1) and carcinosarcomas
(n=1) were classified as type 2 cancers.
Classification of patients to metformin users and non-users was
based on the ADM being used at the time of endometrial cancer
diagnosis. Patients were classified as metformin users if they had
used metformin alone or combined with some other oral ADMs. On
the other hand, the patients were categorised as metformin non-users
if they used only other forms of oral ADMs, insulin (alone or
combined with metformin and/or other oral ADMs) or did not use
any ADM.
The follow-up of the patient began at the time the endometrial
cancer surgery was done, except for patients who were not eligible
for surgery (n=14). In those cases, the start of the follow-up was the
date of diagnosis from the endometrial sample. Follow-up ended at
the time of death or closure of the follow-up period (7th August
2018). The median follow-up time was 65 months.  
Statistical analysis. Statistical analysis was performed with IBM
SPSS Statistics, version 25 (IBM Corporation, Armonk, NY, USA)
and GraphPad Prism, version 8.0.2 (GraphPad Software, San Diego,
CA, USA) software. Comparisons between two medication groups
were evaluated using the two-sample t-test and Mann-Whitney U-
test for continuous variables and Pearson chi-square and Fisher’s
exact test for categorical variables. FIGO stage was distributed into
two categories – early or advanced. Early stage included FIGO
stages I A and I B, while advanced stage included stages II, III and
IV. Kaplan-Meier curves with the log-rank test were applied to the
survival analysis. OS was calculated from the time of surgery or
cancer diagnosis to the time of death. Progression-free survival
(PFS) was calculated from the time of the surgery or cancer
diagnosis to the date of radiological progression. Cox regression
analysis was applied for multivariate analysis, where the
traditionally most important prognostic factors – age, histology and
the stage of endometrial cancer – were included along with
metformin use in the model. In all statistical analyses, p-values
<0.05 were considered statistically significant.
Results
Patient and tumour characteristics. There were 121 women
with T2D diagnosed with endometrial cancer between 2007
and 2014 at Oulu University Hospital in Finland (Figure 1).
The metformin user group had 58 women, of which 35 were
using metformin alone, while 23 were using metformin
combined with some other oral ADMs. The metformin non-
user group had 63 patients – of which 37 were insulin users,
8 were using some other oral ADMs and 18 were not using
any ADMs.
The mean age for endometrial cancer diagnosis was 70.5
years among the metformin users and 71.2 years among the
metformin non-users (p=0.67) (Table I). The metformin non-
users were slightly more obese than the metformin users, as
median BMI was 33.0 in the metformin users and 36.0 in the
metformin non-users (p=0.11). Parity and the presence of
fatty liver were similar in both groups.  
There were more adverse prognostic factors in the
metformin user group (Table II). Intriguingly, type 2
histology (p=0.018) and the presence of LVI (p=0.04) and
deep myometrial invasion (p=0.035) were more common in
the metformin user group (Table II). There was also a trend
of more advanced-stage endometrial cancers in the
metformin user group (p=0.07). However, there were no
statistically significant differences in tumour size (p=0.61),
peritoneal cytology (p=0.98) and ER status (p=0.33)
between the medication groups. In addition, residual tumour
after surgery (p=0.12), the number of patients who received
adjuvant treatment (p=0.12) and the number of patients who
were not eligible for operation (p=0.123) did not show
statistically significant differences between metformin users
and non-users.
Overall survival. As expected, univariate analysis showed
OS was worse in patients with type 2 endometrial cancers
than in patients with type 1 (p=0.0000018) (Figure 2).
Similarly, OS was worse in patients with advanced-stage
cancer (p=0.000013), patients ≥65 years of age (p=0.006)
and patients with deep myometrial invasion (p=0.0000093).
ER status (p=0.79) and BMI (p=0.82) showed no association
with OS.
Univariate analysis of the whole cohort revealed that
metformin use had no association with OS (p=0.67).
Furthermore, metformin use was not associated with OS
when assessed separately in subgroups of type 1 histology
(p=0.19), type 2 histology (p=0.21), superficial myometrial
invasion (p=0.27), deep myometrial invasion (p=0.57),
presence of LVI (p=0.31), early-stage cancer (p=0.33),
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advanced-stage cancer (p=0.64), ER-negative endometrial
cancers (p=0.87), ER-positive endometrial cancers (p=0.57),
higher BMI class (p=0.22) and older patients (p=0.35).
Similarly, Cox regression analysis showed that metformin
use was not associated with OS after adjusting for histology
type, stage and patient’s age [Hazard ratio (HR)=0.86, 95%
confidence interval (CI)=0.41-1.79] (Table III). In addition,
advanced stage and type 2 histology were associated with
poorer OS in the patients ≥65 years old subgroup while
advanced stage of cancer was only associated with poorer
OS in the patients of type 2 histology subgroup.
Progression-free survival. Similar with OS, PFS was worse
in type 2 histology (p=0.000004), more advanced stage
(p=0.000000000001) and deep myometrial invasion
(p=0.0003) in univariate analysis (Figure 3). However, older
age (p=0.11), higher BMI (p=0.54) and ER negativity
(p=0.36) of the tumour showed no association with PFS.
In the whole cohort, metformin use was not associated
with PFS (p=0.1) in univariate analysis. However, metformin
use was associated with poorer PFS in type 2 histology
(p=0.015). In addition, metformin use is associated with
poorer PFS in older patients (p=0.015). Nevertheless,
metformin use was not linked with PFS when separately
assessed in subgroups of type 1 histology (p=0.2), superficial
myometrial invasion (p=0.18), deep myometrial invasion
(p=0.5), higher BMI class (p=0.091), presence of LVI
(p=0.1), ER-positive cancer (p=0.26), ER-negative cancer
(p=0.06), early-stage cancer (p=0.44) or advanced-stage
cancer (p=0.51). However, in the Cox regression analysis, the
advanced stage was the only factor that was associated with
poorer PFS after adjusting for metformin use, histology and
age (Table III). When Cox regression analysis was done only
among patients with either type 2 histology or among those
≥65 years age, in both of these analyses, only advanced stage
was an adverse prognostic factor for PFS.
Discussion
Metformin has shown various anti-cancer effects on
endometrial cancer cells in preclinical studies. In addition to
its growth inhibitive effect (12), metformin seems to
sensitise endometrial cancer cells to both chemotherapy (18)
and progestins (19).
In a small clinical study, preoperative use of metformin
was associated with lower cell proliferation, Ki-67
expression, in endometrial cancer (20). Contrary to this
finding, a recent phase III study did not find reduced tumour
proliferation in endometrial cancer among metformin users
(21). Metformin has also been found to prevent tamoxifen-
associated endometrial proliferative changes in breast cancer
patients (22).
Thus, contrary to most previous results, in the current
hospital-based cohort study, metformin use at the time of
endometrial cancer diagnosis in women with T2D was found
to be associated with poorer prognostic factors, but no
associations with either OS or PFS were found. Although the
majority of previous retrospective cohort studies have
indicated that metformin use is associated with better
survival in patients with endometrial cancer, this evidence is
not robust. Few studies have observed a better OS among
metformin users with endometrial cancer, including all
histological endometrial cancer types (23, 24) while better
OS was only noted in non-endometrioid subtype in one study
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Figure 1. Distribution of antidiabetic medication (ADM).
(25). In contrast to this, a lower risk for recurrence has been
reported in type 1 endometrioid cancers in metformin users
in another study (26).
On the other hand, similar to our study, some studies have
not observed any association between metformin use and
survival in patients with endometrial cancer (27-29). In our
previous register-based studies, metformin use was not
associated with lower endometrial cancer-related mortality
in either endometrioid or non-endometrioid histologies, but
metformin users had lower mortality from other causes
among endometrioid endometrial cancer patients (30, 31).
In a previous meta-analysis, no association between
metformin use and endometrial cancer risk was seen (16);
however, histological subtypes were not analysed separately.
No association between metformin use and non-
endometrioid endometrial cancer incidence was seen in our
previous study (31), rather, metformin ever-use was linked
with increased risk for endometrioid endometrial cancer
among the patients compared to those who had never used
metformin (32).
In our present study, metformin use was associated with
poorer prognostic factors, which may interfere with the
survival results. The most established negative prognostic
factors for endometrial cancer, advanced-stage cancer and
type 2 histology were also the most important factors
impacting on survival in our study, suggesting that the cohort
was representative. However, analysing histological subtypes
separately is not reliable due to the small amount of type 2
cancers, particularly the non-endometroid type (n=30). In
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Table I. Patient characteristics in the two medication groups: metformin
users and non-users. STD: Standard deviation, BMI: body mass index,
WPRT: whole-pelvic radiation therapy. Significant p-Value is given in
bold.
                                                Metformin         Metformin         p-Value
                                                      users               non-users
                                                    (n=58)                (n=63)
Age at diagnosis (years)                                                                       
  Mean                                           70.5                    71.2                 0.667
  STD                                            8.56                    9.36                      
  Min                                               51                       51                       
  Max                                              88                       88                       
Age group at diagnosis                                                                        
  <65 years                                     19                       14                   0.194
  ≥65 years                                     39                       49                       
BMI (kg/m2)                                                                                         
  Median                                        33.0                    36.0                 0.106
  Range                                        19-55                  22-65                    
  Missing                                         4                         6                        
BMI class (kg/m2)                                                                                
  <35                                               34                       21                   0.008
  ≥35                                               21                       36                       
  Missing                                         4                         6                        
Menopause age                                                                                     
  Premenopausal                              2                         3                    0.479
  Under age 50                                6                         9                        
  50-53 years old                            24                       26                       
  ≥54 years old                               18                       11                       
  Missing                                         8                        14                       
Fatty liver                                                                                              
  Yes                                                21                       21                   0.315
  No                                                 16                       25                       
  Missing                                        21                       17                       
Parity                                                                                                     
  Median                                          2                         2                    0.317
  Range                                          0-9                     0-13                     
Adjuvant treatment                                                                               
  None                                             27                       31                   0.307
  WPRT                                           11                       11                       
  Chemotherapy                              13                        6                        
  Vaginal brachytherapy                  4                         8                        
  Intracavitary radiation                  2                         6                        
  Hormonal treatment                     1                         1                        
Table II. Tumour characteristics in the two medication groups:
metformin users and non-users. ER: Oestrogen receptor. Significant p-
Values are given in bold.
                                                 Metformin         Metformin         p-Value
                                                    users               non-users
                                                    (n=58)                (n=63)
Histology                                                                                             
  Type 1                                          38                       53                    0.018
  Type 2                                          20                       10                      
Stage                                                                                                    
  Early (IA-IB)                               37                       47                    0.07
  Advanced (≥II)                            19                       11                      
  Missing                                          2                         5                      
Deep myometrial invasion                                                                  
  Yes                                               26                       15                    0.035
  No                                                28                       38                      
  Missing                                          4                       10                      
Lymphovascular invasion                                                                   
  Yes                                               24                       12                    0.04
  No                                                31                       37                      
  Missing                                          3                       14                      
ER status                                                                                             
  Positive                                        49                       51                    0.33
  Negative                                         7                       12                      
  Missing                                          2                         0                      
Peritoneal cytology                                                                             
  I-II                                                41                       42                    0.976
  III                                                   2                         2                      
  IV                                                   3                         2                      
  V                                                    2                         2                      
  Missing                                        10                       15                      
Residual tumour after surgery                                                             
  No                                                49                       52                    0.118
  Yes                                                 4                         0                      
  No operation                                  4                       10                      
  Missing                                          1                         1                     
previous studies, metformin use was not linked to more
aggressive histology or more advanced stage (23-26, 28, 29).
However, similar to our study, metformin users were
younger in some of the previous studies (24, 30), while
others have not reported such a difference (23, 25, 26). In
some studies, metformin users had higher BMI than
metformin non-users, which is in contrast to our findings
(26, 28, 29). Also, a better OS in metformin users with
higher BMI has been reported (28). 
The strengths of this study include reliable data on patient
and cancer characteristics, and, over five-year median follow
up. We had the patients’ data at the time of endometrial
diagnosis, such as BMI and parity, and cancer-related data
such as ER status and myometrial invasion, which are
usually missing in register-based studies. On the other hand,
as a limitation, information on the cause of death was not
available and the sample size was not very extensive due to
the single-institution based records. The information on
duration and severity of diabetes and dose of the used
medications were lacking, which might lead to bias, as
longer duration of diabetes is associated with, for example,
increased cardiovascular mortality (33). We presumed
continuous ADM exposure after the endometrial cancer
operation, though we could not verify the duration of
medication use through prescription data.
We observed heterogeneity among the medication groups,
as multiple medication use is common in patients with T2D,
which is consistent with the previous retrospective clinical
studies. The metformin non-user group included 22 patients
who also used insulin alongside metformin. Although the
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Figure 2. Kaplan-Meier curves demonstrate associations between (a) histology, (b) myometrial invasion (c) stage or (d) metformin use and overall survival.
majority of previous epidemiological studies have classified
patients as metformin ever-users or metformin never-users, we
decided to categorise those patients who used metformin along
with insulin into the metformin non-user group. In a Danish
study, insulin initiation was a stronger predictor of death from
other causes in many types of cancer itself (34). Also, in one
of our previous studies, insulin use was associated with
increased mortality from other causes than endometrial cancer
(30). Furthermore, mortality from cancer is increased in
patients who use metformin or sulphonylureas with
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Figure 3. Kaplan-Meier curves demonstrate associations between (a) histology, (b) myometrial invasion (c) stage or (d) metformin use and
progression-free survival.
Table III. The results of multivariate analysis. Significant p-Values are given in bold.
                                                                             Overall survival                                                                       Progression-free survival                 
                                     Hazard ratio           95% Confidence interval            p-Value          Hazard ratio        95% Confidence interval           p-Value
Stage                                   2.279                           1.038-5.006                        0.04                     16.001                       4.225-60.602                   0.00004
Histology                            3.516                           1.688-7.322                        0.001                    2.357                        0.734-7.566                     0.15
Age at diagnosis                 1.058                           1.012-1.106                        0.013                    0.996                        0.937-1.057                     0.886
Metformin use                    0.858                           0.411-1.794                        0.685                  1.081                        0.357-3.266                     0.891
subsequent insulin treatment compared with patients not using
insulin (35). Insulin is not only an important regulator of cell
metabolism but also a growth factor for cancer cells in vitro
via its receptor and insulin-like-growth factor 1 receptor (36).
The current knowledge and data from the Cancer Genome
Atlas (TCGA) define four clinically distinct endometrial
cancer types based on their p53 mutational burden,
exonuclease domain of the DNA polymerase epsilon (POLE)
mutations and microsatellite instability (37, 38). We were
unable to recategorize our endometrial cancer cases
according to TCGA. Lack of information on p53 mutation
status in our study is probably a minor limitation since most
grade 3 endometrioid carcinomas with p53 mutation would
anyway have a poor prognosis and belong to the type 2
cancer group. POLE mutation analysis is not yet available in
every-day cancer diagnostics, so these rare cancers with p53
mutation but better prognosis are not currently identified.
Microsatellite instability (MSI) status was not analysed in
the primary diagnostics in our patient group.
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